were further divided into four subgroups: group 1 (HER2+, HR+) N = 34; group 2 (HER2+, HR−) N = 23; group 3 (HER2−, HR+) N = 123. Group 4 (HER2−, HR−) N = 23. The strength of the associations between the uPA/PAI-1 expression and biological characteristics/subgroups were tested with Kruskal-Wallis H test (multiple-group caomparison) and Mann-Whitney U test (paired-group comparison).

Results: Our findings indicate a positive association between HER2 status and uPA ($p < 0.002$) but no association between HER2 and PAI-1 ($p = 0.445$) was found. The levels of uPA were significantly different between the four subgroups, with the highest levels observed in HER2+HR− subgroup 2. Paired comparisons showed significantly higher uPA levels in HER2+HR− subgroup compared to HER2+HR+ ($p = 0.027$) as well as compared to HER2−HR+ subgroup ($p < 0.001$). The levels of PAI-1 were not significantly different between the four subgroups. However, pair comparisons still showed borderline difference in PAI-1 levels between HER2+HR+ and HER2+HR− subgroup ($p = 0.047$).

Conclusion: In our collective of EBC patients a positive association between HER2 status and uPA was found, however no association between HER2 and PAI-1 was confirmed. The levels of PAI-1 did not differ significantly in the four molecular subgroups defined according to both, HER2 and HR status. Our limited observation points out to a possible independent prognostic value of PAI-1 in the subsets of HER2+ EBC patients.

457 Poster

Does progesterone receptor status provide a predictive value for adjuvant endocrine therapy in breast cancer patients?

E.H. Park[1], J.S. Lee[1], H.J. Kim[1], B.H. Son[1], S.L. Choi[1], W.S. Lim[1], S.H. Ahn[1]. [1]*Asan Medical Center, Department of Surgery, Seoul, Korea*

Background: The predictive value of estrogen receptor (ER) status for adjuvant endocrine therapy in breast cancer patients has been widely proven in many clinical trials reported previously. However, the predictive significance of progesterone receptor (PR) is controversial in an adjuvant setting. The aim of this study was to evaluate the efficacy of hormone therapy according to progesterone receptor expressions.

Material and Methods: The authors retrospectively evaluated clinical data of 1,642 ER-positive breast cancer patients who received adjuvant tamoxifen between January 1993 and December 2002 at Asan Medical Center. The number of patients of ER+/PR+ group was 1,242 (75.6%) and ER+/PR− group was 400 (24.4%). The tumor characteristics, incidences of recurrence and survival rates of the patients were examined.

Results: The mean age of the ER+/PR+ group was younger than that of the ER+/PR− group (46.3 vs 49.3 years, $p < 0.001$). The mean size of ER+/PR+ group was 2.81 ± 1.78 and that of ER+/PR− group was 2.63 ± 1.74 cm ($p = 0.08$). Early breast cancer proportion of the ER+/PR+ group was higher than that of the ER+/PR− group (49.8 vs 43.2%, $p = 0.03$) while advanced breast cancer proportion of the ER+/PR+ group was lower than that of the ER+/PR− group (50.2% vs 56.9%, $p = 0.03$). There were no difference in the LN metastasis and stage, HER2/neu expression between the two groups. With a median of 40 months follow-up, there was no significant difference between the two groups with regard to overall survival (OS) (94.7 vs 90.3%, $p = 0.08$). The 5-year disease free survival (DFS) for ER+/PR+ and ER+/PR− groups were 86.6 and 83.7%, respectively ($p < 0.001$). We classified the ER+ patients into three strata by age (<35, 35−50, $\geqslant$50 years). There was no significant difference in DFS and OS between the two groups in the <35 stratum and the $\geqslant$50 stratum. In contrast, the ER+/PR− group had a worse prognosis in the 35−50 stratum with regard to both DFS (<0.001) and OS ($p = 0.015$).

Conclusion: The present study suggests that PR receptor expression is predictive factor of adjuvant endocrine therapy for ER+-breast cancer patient regard to DFS and OS.

458 Poster

Expression of cyclin D1 and bcl-2 in infiltrative ductal carcinoma of the breast – their correlations and clinical implications

M. Chung[1], Y. Hong[1], H. Yoon[1], B. Kwak[2]. [1]*Hanyang University Medical Center, Surgery, Seoul, South Korea;* [2]*DongGuk University Hosipital, Surgery, Seoul, South Korea*

Background: Cyclin D1 and bcl-2 are involved in cell proliferation and apoptosis in tumor development and commonly expressed in breast cancer. A few laboratory reserches about correlation between cyclin D1 and bcl-2 expression were published but there are few clinical reports. The study was designed to analyze the expression of cyclin D1 and bcl-2 and their clinical implications in breast cancer.

Materials and Methods: Immunohistochemical expressions of cyclin D1, bcl-2 were studied in 342 infiltrative ductal carcinoma cases and were compared with clinicopathologic parameters such as age, tumor size, histologic grade, lymph node status, p53, c-erbB2 and estrogen receptor (ER) positivity.

Results: Cyclin D1 expression was found in 86 of 342 cases (25.1%). Bcl-2 was found to be positive in 227 of 342 cases (66.4%). The overexpression of bcl-2 was associated with the high expression of cyclin D1 ($p = 0.0001$). Correlation was detected between both cyclin D1 and bcl-2 and ER positivity ($p = 0.000$). There was a reverse correlation between bcl-2 and histologic grade ($p = 0.001$). bcl-2 overexpression group had better disease free survival in 3 year follow up.

Conclusions: Higher expression of cyclin D1 was associated with bcl-2 overexpression. Positive expression of ER was associated with high cyclin D1 and bcl-2 expression. Bcl-2 has tendency to have a positive clinical outcome.

459 Poster

HER2 and SPARC status in tumors may play an important role in the relative effectiveness of nanoparticle albumin-bound (nab®) paclitaxel versus polysorbate-based docetaxel

N. Desai[1], V. Trieu[1], L. Hwang[1], R. Wu[1], M. Hawkins[1], P. Soon-Shiong[1], W. Gradishar[2]. [1]*Abraxis BioScience LLC, R&D, Los Angeles CA, USA;* [2]*Northwestern University, Feinberg School of Medicine, Chicago IL, USA*

Background: *Nab*-paclitaxel (Abraxane®) is an albumin-bound 130-nm particle form of paclitaxel that demonstrated higher efficacy and was well tolerated compared to solvent-based paclitaxel (Taxol®) and docetaxel (Taxotere®) in clinical trials for metastatic breast cancer. *Nab*-paclitaxel enhances tumor targeting through gp60 and caveolae-mediated endothelial transcytosis and the association with the albumin-binding protein SPARC in tumor microenvironment. HER2, which is overexpressed in about 25−30% of breast cancers, is associated with increased tumor survival and resistance to paclitaxel. SPARC, which is overexpressed in about 50% of breast cancers, is associated with increased tumor invasion and known to be a poor prognostic factor in breast cancer. The goal of this study was to evaluate the importance of HER2 and SPARC status in determining the relative efficacy of *nab*-paclitaxel compared with solvent-based docetaxel.

Materials and Methods: Maximum tolerated dose (MTD) of *nab*-paclitaxel and docetaxel were previously determined as >120 mg/kg and 15 mg/kg respectively on a q4d$\times$3 schedule. HER2 and SPARC status in tumors was analyzed by immunohistochemistry. The antitumor activity of solvent-based docetaxel (15 mg/kg) was compared to *nab*-paclitaxel in breast tumor xenografts MX-1 (equidose level of 15 mg/kg, qwk$\times$3), MDA-MB-231 (120 and 180 mg/kg, q4d$\times$3) and MDA-MB-231/HER2+ (50 and 120 mg/kg, q4d$\times$3). Additional tumor xenografts (LX-1 lung, PC3 prostate, and HT29 colon) were also studied. Tumor volume and body weights were monitored.

Results: MDA-MB-231 and MX-1 breast cancer and the LX-1 lung cancer lines were HER2 negative and low in SPARC. The HER2 positive tumors had variable SPARC expression, with MDA-MB-231/HER2+ < PC3 < HT29. *Nab*-paclitaxel at sub-MTD dose was significantly more effective than solvent-based docetaxel at its MTD in the three HER2-negative tumors. In HER2-positive tumors, *nab*-paclitaxel was equal to or better than solvent-based docetaxel in tumors with medium to high SPARC levels (PC3 and HT29), but not in MDA-MB-231/HER2+ tumors with low SPARC expression.

Conclusions: The relative efficacy of *nab*-paclitaxel vs. solvent-based docetaxel was significantly higher in HER2-negative tumors. In HER2 positive tumors, the relative efficacy of *nab*-paclitaxel increased with increasing SPARC expression. HER2 and SPARC expression may be useful biomarkers in determining antitumor effectiveness for taxanes.

460 Poster

External validation in ONCOPOOL of updated survival according to the Nottingham Prognostic Index (NPI)

K. Holli[1], R.W. Blamey[2], G.R. Ball[3], I.O. Ellis[4], S. Pinder[5]. [1]*ONCOPOOL, Surgery, Tampere, Finland;* [2]*ONCOPOOL, Breast Institute, Nottingham, United Kingdom;* [3]*Nottingham University, Breast Institute, Nottingham, United Kingdom;* [4]*Nottingham City Hospital, Pathology, Nottingham, United Kingdom;* [5]*Royal Infirmary Hospital, Pathology, London, United Kingdom*

From Nottingham City Hospital (NCH) data the NPI was described and validated in the early 1980's. Case survival has markedly improved and new survival figures for cancers treated in the 1990's NPI groups have been published (n = 2235).

ONCOPOOL is a dataset of primary breast cancer assembled as an EC FP5 project in 12 European Breast Units. 17,604 cases treated in the 1990's were available for this analysis.

There are no significant differences in survival in any NPI group between the NCH set and ONCOPOOL nor do overall distributions to prognostic groups differ significantly.